Table 2.
Comparison of clinical findings in T2DM with renal impairment according to renal resistance index.
Parameters | R I< 0.66 (n = 213) | RI ≥ 0.66 (n = 256) | P value |
---|---|---|---|
Age, (years) | 49.20 ± 10.47 | 53.37 ± 9.64 | <0.001 |
Gender, (male, %) | 132(61.97) | 166 (64.84) | 0.526 |
BMI, (kg/m2) | 25.67 ± 3.64 | 24.87 ± 3.31 | 0.013 |
SBP, (mm Hg) | 136.73 ± 20.47 | 147.62 ± 23.17 | <0.001 |
DBP, (mm Hg) | 84.92 ± 11.53 | 83.96± 12.69 | 0.398 |
Duration of diabetes, (months) | 51.46 ± 55.12 | 95.69 ± 61.01 | <0.001 |
Duration of diabetes ≥ 60, months (%) | 70 (32.86) | 169(66.01) | <0.001 |
HbA1c, (%) | 7.70 ± 1.88 | 7.94 ± 2.33 | 0.284 |
HbA1c ≥ 7, (%) | 97(45.54) | 118 (46.09) | 0.832 |
FBG, (mmol/L) | 7.17 ± 3.08 | 7.48 ± 3.54 | 0.313 |
Hemoglobin, (g/L) | 126.00 ± 23.53 | 110.60 ± 23.95 | <0.001 |
PLT, (10^9/L) | 211.45± 82.92 | 200.98 ± 76.00 | 0.157 |
Serum albumin, (g/L) | 36.13 ± 10.45 | 34.26 ± 8.37 | 0.034 |
TG, (mmol/L) | 2.44 ± 1.97 | 2.03 ± 1.75 | 0.018 |
TC, (mmol/L) | 5.47 ± 2.24 | 5.48 ± 1.75 | 0.920` |
Scr, (μmol/L) | 106.47± 60.54 | 144.76 ± 83.96 | <0.001 |
eGFR, (ml/min/1.73m2) | 79.03 ± 35.72 | 59.22 ± 32.71 | <0.001 |
BUN, (mmol/L) | 7.01 ± 3.21 | 8.56 ± 3.90 | <0.001 |
Uric acid, (μmol/L) | 375.98 ± 103.04 | 381.33 ± 91.05 | 0.555 |
Urinary protein, (g/24 h) | 3.03 ± 3.96 | 3.73 ± 3.47 | 0.054 |
Hematuria (%) | 134 (62.91) | 184 (71.88) | 0.056 |
Cardiovascular disease (%) | 78 (36.61) | 101 (39.45) | 0.479 |
Hypertension (%) | 121 (56.81) | 191 (74.61) | 0.003 |
DR (%) | 63 (29.58) | 163 (63.67) | <0.001 |
Nephrotic syndrome (%) | 40 (18.78) | 69 (26.95) | 0.037 |
BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; HbA1c, glycosylated hemoglobin; FBG fasting blood glucose; PLT, platelet; TG triglyceride; TC total cholesterol; Scr serum creatine; BUN blood urea nitrogen; DR, diabetic retinopathy. Data were presented as the mean ± standard, the median with range or counts and percentages. A two-tailed p < .0.05 was considered statistically significant.